Log in to save to my catalogue
Log in to save to my catalogue

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

| Ask | Become a Library member

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1705730710

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

About this item

Publication information

Publisher

United States: Massachusetts Medical Society

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Among patients coinfected with HIV-1 and HCV, a sustained HCV virologic response was reported in 97% of patients treated with 12 weeks of daclatasvir plus sofosbuvir.
Liver disease is a leading cause of death among patients with human immunodeficiency virus type 1 (HIV-1) infection.
1
Coinfection with HIV-1 and hepatitis C virus (HCV) appe...

Alternative Titles

Full title

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1705730710

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1705730710

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1503153

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections